Two major pharmaceutical companies are teaming up to treat malignant pleural mesothelioma. Aduro Biotech and Merck are collaborating on an upcoming clinical trial testing CRS-207 with Keytruda (pembrolizumab). Separately, both of these drugs have had very promising results for mesothelioma...
Read More
A new study revealed that individuals who are exposed to asbestos earlier in their career are at a higher risk of developing pleural mesothelioma.The study published in the BMJ...
Read PostA potential pleural mesothelioma treatment has received Humanitarian Use Device (HUD) designation from the U.S. Food and Drug Administration (FDA). Receiving HUD designation may...
Read PostA recent Centers for Disease Control (CDC) study unveiled that the state of Maine has the highest rate of asbestos-related deaths. Every year in the United States approximately...
Read PostA few weeks ago Jenna Campagna and I had the privilege of sitting down with members of the support staff at the Mesothelioma Treatment Center in Houston, Texas. The Mesothelioma...
Read PostA new phase 2 study is using a combination of immunotherapies to treat malignant pleural mesothelioma. In this trial, researchers are testing the safety and efficacy of two...
Read PostRecently, NAPA Auto Parts and Genuine Parts Corp. were found liable in an asbestos-related death of a heavy equipment operator. The trial lasted for more than 12 weeks and found...
Read PostA recent study published in The Lancet Oncology has revealed that the immunotherapy drug pembrolizumab may be an effective 2nd line treatment for mesothelioma. Pembrolizumab is...
Read PostA website called CaringBridge is bringing a new method of communication between loved ones when there is a health crisis. Social media allows us to share our experiences and...
Read PostThis week is Global Asbestos Awareness Week. The Asbestos Disease Awareness Organization (ADAO) sponsors this event annually during the first week of April. The goal of this week...
Read Post
